Akero Therapeutics Inc. (AKRO) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Akero Therapeutics Inc.

    NASDAQ: AKRO · Real-Time Price · USD
    44.72
    0.69 (1.57%)
    At close: Sep 05, 2025, 3:59 PM
    44.72
    0.00%
    After-hours: Sep 05, 2025, 05:38 PM EDT

    Akero Therapeutics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 n/a n/a n/a n/a
    Cost of Revenue
    		 18K 29K 260K 244K
    Gross Profit
    		 -18K -29K -260K -244K
    Operating Income
    		 -285.42M -172.87M -115.16M -100.89M
    Interest Income
    		 38.03M 24.21M 3.86M 109K
    Pretax Income
    		 -252.06M -151.76M -112.03M -100.78M
    Net Income
    		 -252.06M -151.76M -108.91M -100.74M
    Selling & General & Admin
    		 37.93M 31.07M 29.87M 19.13M
    Research & Development
    		 247.5M 141.8M 85.28M 81.76M
    Other Expenses
    		 n/a n/a n/a n/a
    Operating Expenses
    		 285.42M 172.87M 115.16M 100.89M
    Interest Expense
    		 4.67M 3.1M 739K n/a
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 285.42M 172.87M 115.16M 100.89M
    Income Tax Expense
    		 n/a n/a -3.12M -41K
    Shares Outstanding (Basic)
    		 67.14M 52.57M 38.98M 34.83M
    Shares Outstanding (Diluted)
    		 67.14M 52.57M 38.98M 34.83M
    EPS (Basic)
    		 -3.75 -2.89 -2.87 -2.89
    EPS (Diluted)
    		 -3.75 -2.89 -2.87 -2.89
    EBITDA
    		 -285.42M -148.63M -111.03M -100.53M
    EBIT
    		 -256.73M -148.66M -111.29M -100.78M
    Depreciation & Amortization
    		 -28.7M 29K 260K 244K

    Add to Watchlist